Newly public Latigo, Eikon each tap new execs

Two biotechs that went public this year, Latigo and Eikon, each made key executive appointments as their programs advance in the clinic.

Latigo Biotherapeutics Inc. (NASDAQ:LTGO) named Naomi Lowy SVP of global regulatory affairs. She arrives from FDA, where she was Deputy Director of the Division of Anesthesia, Addiction Medicine and Pain Medicine (DAAP). Latigo’s oral Nav1.8 inhibitor LTG-001 is a non-opioid analgesic moving into late-stage testing; the company grossed $397.4 million, including the full exercise of its underwriters’ option, in its August IPO...